Filing summary
Entity and period: The supplied filing is AVROBIO, Inc.’s Form 10-K for the fiscal year ended December 31, 2022, filed March 23, 2023 (Nasdaq: AVRO). It does not appear to be a filing for Tectonic Therapeutic, Inc. The financial results below are annual figures; the filing text does not provide a separate 2022 fourth-quarter income statement.
Business context
AVROBIO was a clinical-stage gene therapy company developing autologous hematopoietic stem cell (HSC) gene therapies for rare diseases. Its pipeline included programs for Gaucher disease (AVR-RD-02), cystinosis (AVR-RD-04), Hunter syndrome (AVR-RD-05) and Pompe disease (AVR-RD-03). The company had no product sales and remained dependent on external financing.
Financial performance and position
| Metric | 2022 | 2021 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $72.2 million | $83.1 million |
| General and administrative expense | $33.2 million | $35.7 million |
| Total operating expenses | $105.4 million | $118.8 million |
| Net loss | $105.9 million | $119.1 million |
| Net loss per share, basic and diluted | $2.42 | $2.78 |
| Net cash used in operating activities | $97.2 million | $98.0 million |
At December 31, 2022, cash and cash equivalents were $92.6 million, down from $189.6 million a year earlier; total assets were $103.9 million, total liabilities $28.6 million, and stockholders’ equity $75.4 million. The company reported $15.0 million of loan principal outstanding (carrying value, net of discount, $15.3 million). Interest-only payments were scheduled through November 2024, with maturity on October 1, 2026. Gross margin and other product-level profitability measures are not meaningful because there was no product revenue.
Material changes and outlook
- Operating expenses and net loss decreased year over year, primarily reflecting lower personnel costs after a January 2022 workforce reduction of approximately 23%, alongside lower preclinical and manufacturing costs.
- AVR-RD-01, the Fabry disease program, was deprioritized and enrollment in its Phase 2 trial stopped after variable engraftment data in recently dosed patients. The company also lost access to $20 million of milestone-contingent loan funding tied to that program.
- AVR-RD-02 was in a Phase 1/2 Gaucher type 1 trial; four patients had been dosed as of the reported interim data. A global Phase 2/3 Gaucher type 3 trial was planned for the second half of 2023, subject to regulatory alignment.
- AVR-RD-04’s collaborator-sponsored cystinosis trial had dosed six patients. The company planned a company-sponsored, registration-enabling Phase 1/2 trial in the second half of 2023, subject to regulatory clearance.
- A collaborator-sponsored Phase 1/2 trial of AVR-RD-05 for Hunter syndrome was expected to start in 2023. The company no longer expected to initiate a Pompe disease trial for AVR-RD-03 in 2023, prioritizing Gaucher disease and cystinosis.
- Management’s MD&A estimated that year-end cash would fund operating expenses and capital needs into the first quarter of 2024. However, the financial statement note says cash may not be sufficient to fund operations for at least 12 months from issuance and identifies substantial doubt about the company’s ability to continue as a going concern. The auditor’s report also highlights this substantial doubt.
Risks, contingencies and unusual items
- Financing and going concern: The company expected significant future losses and said additional capital was necessary. There is no assurance financing would be available on acceptable terms, or at all; failure to raise funds could require delaying, reducing or ending development or considering strategic alternatives.
- SVB: Silicon Valley Bank was closed on March 10, 2023, after the balance-sheet date. The company reported that depositors would have access to funds following government action, but its loan agreement required substantially all cash to be held at SVB. SVB temporarily waived related deposit covenants while the company pursued alternative banking arrangements and account-control agreements.
- Debt and liquidity restrictions: The loan is secured by substantially all company assets other than intellectual property and includes restrictive covenants. The lender’s consent was required for a potential additional $15 million draw; availability was not assured.
- Development and safety: Programs were early-stage, interim trial results were preliminary, and success in later trials or regulatory approval was uncertain. HSC gene therapy, myeloablative conditioning, manufacturing comparability, patient enrollment and reliance on sole-source suppliers present material risks. The filing describes conditioning-related adverse events, including one unresolved amenorrhea event in the four-patient Gaucher type 1 trial at the cited cutoff.
- Other matters: The company reported no material pending litigation and no off-balance-sheet arrangements. It recorded $1.4 million of restructuring expense in 2022. Its Nasdaq minimum-bid-price deficiency was reported cured in February 2023, though continued compliance remained a risk.
Most important facts for investors to verify
- Confirm the issuer: this filing is for AVROBIO, Inc. (AVRO), not Tectonic Therapeutic, Inc.
- Reconcile the stated cash runway into Q1 2024 with the going-concern disclosure stating cash may not cover 12 months from issuance.
- Check current cash, financing actions and access to the SVB loan facility after the March 2023 banking events.
- Track clinical and regulatory progress, enrollment and updated safety and efficacy data for AVR-RD-02, AVR-RD-04 and AVR-RD-05; assess the implications of the Fabry engraftment findings for the broader platform.
- Review loan covenants, repayment terms, potential dilution from equity issuance and the substantial shares reserved for equity awards.